Probi AB (SS:PROB)

Probi AB (publ) researches, manufactures, and sells probiotics for dietary supplements and food companies in North America, South America, Europe, Sweden, the Middle East, Africa, Asia Pacific, and internationally. The company conducts research primarily in the fields of mental, digestive, immune, bone, oral, children's, women's, and senior health, as well as iron absorption. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, chilled diary and plant based products, frozen desserts and ice-cream, powder formulas, and recovery drinks. In addition, the company offers Probi Sensia, a proprietary probiotic strain clinically shown to enhance cognition by boosting learning and working memory; Probi Digestis for support gastrointestinal health; Probi Defendum which provides positive impact on immune health; Probi FerroSorb, a probiotic iron-absorption concept, to support long-term iron status; Probi Osteo for bone health; BLIS by Probi offers unique way to boost oral health with probiotics; Probi LiveBac provides live and active probiotic cultures for dietary supplements and functional food product; and LP299V for human gastrointestinal tract and adhere to intestinal epithelial cells to boost health benefits. It has a collaboration with Örebro University for research into exploration needle free vaccines; University of Gothenburg to investigate the effects of probiotic strain LP299V on iron absorption; Wageningen University & Research to understand the molecular interactions occurring between microbes and its hosts; University of Umeå to investigate the effects of the strain LP299V on iron status in female athletes; and University of Aberdeen to characterize bacterial isolates with next generation probiotics. Probi AB (publ) was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.